Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population
PRECISION1 tumor-agnostic trial...

Related Keywords

Boston ,Massachusetts ,United States ,Brian Mcmorran ,Marcy Graham ,Shihe Hou ,Andrew Kwon ,Maria Zalath ,Gopa Iyer ,Sean Wallace ,Khine Nyein Myint ,Normaa Palma ,Igor Vivanco ,Willish Navarro ,Aadi Bioscience ,Foundation Medicine ,Twitter ,Prnewswire Aadi Bioscience Inc ,Company Annual Report On Form ,Linkedin ,Nasdaq ,International Conference On Molecular ,Aadi Bioscience Inc ,Molecular Targets ,Cancer Therapeutics ,Poster Session ,Open Label Basket Trial ,Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Markets ,